Why the study?
Chinese herbal medicine is widely used as a complement or alternative treatment in CAD patients after PCI in China, but its association with MACE needed comparison against standard treatment alone.
Does the complement use of Chinese herbal medicine reduce MACE in CAD patients after PCI?
Does the complement use of Chinese herbal medicine reduce MACE in CAD patients after PCI?
Complementary use of Chinese herbal medicine alongside standard therapy may reduce 2-year MACE in CAD patients following PCI.
BACKGROUND: Chinese herbal medicine is widely used as a complement or alternative treatment in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in China. We compared the incidence of the major adverse cardiovascular event (MACE) of CAD patients with or without the complement use of Chinese herbal medicine after PCI. METHODS: In this prospective, observational study that was conducted from September 2016 to August 2019 in Fuwai Hospital (China), we followed up consecutive patients who received PCI treatment for two years. MACE was defined as the composite all-cause mortality, revascularization, and myocardial infarction (MI) and was compared between those using (integrative medicine group) or those not using Chinese herbal medicine as an additional treatment to standard Western medicine, with unadjusted (Kaplan-Meier curves) and risk-adjusted (multivariable Cox regression) analyses. RESULTS: < 0.0001). CONCLUSIONS: For CAD patients after PCI treatment, complement use of Chinese herbal medicine is associated with a lower 2-year MACE incidence. Randomized prospective studies are warranted to provide higher levels of benefit evidence in these patients.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: